Experimental immune cell therapy for B-cell lymphoma or leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests an experimental therapy called CT1195E, a type of 'living drug' made from your own immune cells to fight B-cell cancers that have returned or not responded to standard care. It's a phase 1 study, which means the main goal is to find a safe and effective dose, but you may benefit from the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma or B-cell acute lymphoblastic leukemia (ALL) that has come back or not improved after standard treatments.
- You have tried at least one standard treatment (like chemo or a targeted drug) and it didn't work or you couldn't tolerate it.
- You are generally in good health, able to do daily activities, and have a life expectancy of more than 12 weeks.
- Your heart, liver, kidney, and blood counts are within acceptable levels as shown by blood tests.
- You are willing to use reliable birth control and not donate eggs or sperm for at least 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CT1194D for people with certain B-cell blood cancers that have not responded to or have come back after standard treatment. The therapy is designed to find and destroy cancer cells that carry the CD19 or CD20 marker.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new treatment called CT1194C for patients with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. It aims to see if this treatment can help control the lymphoma and is safe.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Hear when a new Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.